Triangular test applied to the clinical trial of azithromycin against relapses in Plasmodium vivax infections by Ranque, Stéphane et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Malaria Journal
Open Access Malaria Journal  2002,  1 x Methodology
Triangular test applied to the clinical trial of azithromycin against 
relapses in Plasmodium vivax infections
Stéphane Ranque*1, Sékéné Badiaga2, Jean Delmont2 and Philippe Brouqui2
Address: 1Laboratoire de Parasitologie et Mycologie, INSERM U.399, Université de la Méditerranée, Faculté de Médecine, 27 Boulevard Jean 
Moulin, 13385 Marseille CEDEX 5, France and 2Service des Maladies Tropicales et Infectieuses, IFR 48, Hôpital Nord, Chemin des Bourrelly, 13915 
Marseille Cedex 20, France
E-mail: Stéphane Ranque* - stephane.ranque@medecine.univ-mrs.fr; Sékéné Badiaga - s.badiaga@caramail.com; 
Jean Delmont - jpdelmont@mail.ap-hm.fr; Philippe Brouqui - Philippe.Brouqui@medecine.univ-mrs.fr
*Corresponding author
Abstract
Background: Sequential analysis enables repeated statistical analyses to be performed throughout
a trial recruitment period, while maintaining a pre-specified power and type I error. Thus the trial
can be stopped as soon as the information accumulated is considered sufficient to reach a
conclusion. Sequential tests are easy to use and their statistical properties are especially suitable to
trials with very straightforward objectives such as non-comparative phase II trials. We report on a
phase II study based on the triangular test (TT) aiming at assessing the effectiveness of azithromycin
in preventing Plasmodium vivax relapses.
Methods: To test whether the P. vivax relapse rate was either <12% or ≥ 45% in patients treated
with azithromycin, a sequential analysis based on the TT was as used. Patients infected with P. vivax
were treated with azithromycin, 1.2 g daily, for 7 days. The onset of a relapse infection was
monitored.
Results: Five patients presenting with an acute P. vivax infection were included in the study. All the
patients were initially cured. Three patients reported mild gastrointestinal adverse effects. When
the third patient relapsed, the sample path crossed the upper boundary of the TT, and the trial was
stopped.
Conclusions: Using the triangular test, with only a small number of patients, we concluded that
azithromycin was not effective enough in preventing P. vivax relapses to warrant further evaluation
in phase III. It is suggested that a wider use of sequential analysis in phase II anti-infective drugs trials
may have financial and ethical benefits.
Introduction
The purpose of phase II trials is to determine whether a
drug is effective enough to warrant further evaluation in
phase III. For ethical reasons, the smallest number of pa-
tients necessary to reach a firm conclusion should be in-
cluded in a phase II trial. To this end, it is critical to choose
decision methods that allows early cessation when effec-
tiveness or ineffectiveness is clear. Sequential methods,
such as the triangular test (TT), have the required proper-
ties, but although they have been described for many
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years, few clinical trials have yet made use of them. This
paper presents a concrete example of a non-comparative
phase II trial design and analysis based on the TT. In sec-
tion 1, the rationale for using the TT in a phase II trial is
examined. In section 2, an application of the TT to study
the anti-relapse activity of azithromycin on Plasmodium
vivax is described. Finally, in section 3, the impact of using
the TT on the design of the present trial is outlined.
Rationale of the triangular test
Stopping rules in clinical trials
The standard approach in clinical trials is the fixed-sample
analysis. It assumes a single step design in which all data
are simultaneously available, and requires that only one
analysis be performed after a given number N of patients
is included. Stopping rules are a major ethical issue in
clinical trials, since N is often large and data accumulates
gradually over a period which can extend to months or
years. In the usual fixed-sample design, the longer the
time taken for the occurrence of the main response criteri-
on is, the later the analysis is delayed after the beginning
of the trial. Therefore, it is common practice to perform
interim analyses. Supported by ethical motivation, their
objective is to stop the trial early if a treatment effect is de-
tected or alternatively if it appears that there is no treat-
ment effect. But such repeated testing increases the
probability α of wrongly rejecting the null hypothesis: for
example, this probability becomes 14% if five analyses are
performed at the usual 5% level [1]. The use of a more
conservative nominal level of α has been proposed for
each interim analysis to ensure an overall level of α. One
still plans an analysis after N patients according to the
fixed sample design, but interim analyses at level α' are
performed before N patients and the conclusion is
reached, if a significant difference is observed. Otherwise,
the trial goes on until the final analysis after N patients are
included [2]. This hybrid approach combines interim
analyses at a level α' and then, if they are not conclusive,
a final analysis at a level α as in the fixed-sample design.
This does not allow early stopping if there is no treatment
difference. Finally, power calculations are made for the fi-
nal analysis but not for the interim analyses. For these rea-
sons, it seems preferable to use truly sequential methods,
which are designed to allow for repeated testing.
Description of sequential methods
Malariologists are familiar with the sequential analysis ap-
proach since a similar method, the double (or two steps)
lot quality assurance sampling plan [3], is widely used to
assess the level of in vivo antimalarial drug resistance of P.
falciparum within communities. Sequential analysis meth-
ods were first used in the context of industrial quality con-
trol in the late 1920s [4]. Sequential analysis enables
repeated statistical analyses to be performed throughout
the trial recruitment period, while maintaining a pre-spec-
ified α and β error, enabling the trial to be stopped as soon
as the information accumulated is considered sufficient to
reach a conclusion. The use of sequential analysis in clin-
ical trial has been extensively described in [5,6]. Data are
analysed as the results for each participant are obtained.
After each analysis, the decision is made either to continue
the study by enrolling additional participants, to stop the
study with the conclusion that there is a statistically signif-
icant difference, or to stop the study and conclude that
there is no statistically significant difference. In the 1940s,
Wald [7] developed the continuous sequential probability
ratio test (SPRT). The continuous SPRT requires that the
analysis be performed as the outcome for each new pa-
tient becomes available. This makes it difficult to imple-
ment in a many clinical trial settings. Whitehead [8]
proposed the discrete SPRT and the triangular test (TT) for
the design and analysis of phase III trials. Unlike the con-
tinuous SPRT, these two sequential methods allow for dis-
crete data analysis (for example, after every 10 new
patients) and are therefore easier to implement in a varie-
ty of settings. Both the discrete SPRT and the TT have op-
timal properties in terms of average sample needed [9].
They are based on straight line stopping boundaries: the
discrete SPRT using an open continuation region and the
TT a closed continuation region. Therefore, the TT appears
more relevant, because the sample size could theoretically
be infinite using the SPRT. Two statistics are used, the ef-
ficient score Z, and Fisher's information V for the param-
eter of interest. They are both computed under the null
hypothesis H0. Each analysis results in a pair of values for
the Z and V statistics. The corresponding points are plot-
ted on the graph as they become available. The plot of Z
against V is referred to as the sample path. The horizontal
axis corresponds to the statistic V, representing the quan-
tity of information accumulated since the beginning of
the trial. The vertical axis corresponds to the statistic Z,
representing the benefit as compared with the null hy-
pothesis. Two straight lines, the boundaries of the test, de-
lineate a continuation region (located in between these
lines) from the region of non-rejection of the null hypoth-
esis (i.e. no significant improvement, located beneath the
bottom line) to the region of rejection of the null hypoth-
esis (i.e. significant improvement, located above the top
line). The sample path is compared with the stopping
boundaries. If the plotted point lies either above the up-
per boundary or below the lower boundary, the trial has
to be stopped. Bellissant et al.[9,10] applied the discrete
SPRT and the TT to the comparison of an observed success
rate p with p0, as encountered in non-comparative phase
II cancer clinical trials.
Non-comparative phase II trials settings
Phase II pilot efficacy evaluation clinical trials are often
non-comparative. Their usual end point is the proportion
p of eligible patients who respond to the treatment as de-Malaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/13
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fined in the protocol. Their objective is to determine
whether the response rate p is greater than a threshold val-
ue p0, i.e. the largest response rate (or clinical improve-
ment) for which further investigations are not
worthwhile. In statistical terms, the two competing hy-
potheses are the null hypothesis (H0: p ≤ p0) and the alter-
native hypothesis (Ha: p > p0). The sample size N required
by the single stage design as well as the corresponding
threshold C based on the exact binomial distribution of
number of responses S can be computed after choosing p0,
specifying Ha: p = pa (pa being the smallest response rate
for which further investigations are worthwhile), choos-
ing the type I error α, and choosing the power 1-β under
Ha. If S is greater than C after N patients, then H0 is reject-
ed.
Set-up of a triangular test
The description of the set-up of a TT in a non-comparative
phase II trial that follows is adapted from Bellissant et al.
[9,10] where greater details are given. In a phase II study
design aiming to compare an observed event rate p to an
expected event rate p0, the two competing hypothesis are:
H0: p ≤ p0 and Ha: p > p0. The log odds ratio measures the
difference between p and p0:
hence if p = p0 then θ = 0.
The log-likelihood of the data can be written as:
l(p) = S log p + (N - S)log(1 – p),
where S denotes the number of patients who experience a
response (or a success), and N is the number of patient in-
cluded in the study.
The Z and V statistics are respectively the first derivative
and the opposite of the second order derivative of the log-
likelihood evaluated at θ = 0:
If we choose pa, the smallest event rate for which further
investigations are worthwhile, we can specify Ha: p > pa,
and
The boundaries of the test are computed given the type I
error α, and the power 1-β under Ha. The equations of the
boundaries are given by:
Z = a + λ V and Z = -a + 3λV,
where:
and where I denotes the increment in V between two anal-
yses, when discrete analyses are performed every n pa-
tients
I = np0 (1 - p0).
In the case where α ≠ β, based on the assumption that Z is
normal, distributed with mean θV and variance V, we can
use   a corrected value of θa, given by the approximate
formula:
where  Φ(x) denotes the standard normal distribution
function:
and where X ~ N(0,1).
The above section describes the usual design of the TT
aiming to detect any improvement or any increase of the
measured end point (response) rate. In the section that
follows, a non-comparative trial based on the TT, as de-
scribed by Bellissant et al.[9,10] is reported. The measured
end point of the present trial being the relapse after the
treatment of a P. vivax malaria attack, this trial had the pe-
culiarity to have been designed to detect a decrease, and
not an increase, of the end point rate. As a result, the re-
gion of rejection of the null hypotheses (otherwise located
above the top line) was located beneath the bottom line,
and the region of non-rejection of the null hypothesis
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(otherwise located beneath the bottom line) was located
above the top line (Figure 1).
Application of the TT to study the anti-relapse activity of 
azithromycin on Plasmodium vivax
The prevention of relapse infections is the most important
problem in the treatment of Plasmodium vivax malaria. Re-
lapses are clinical attacks that appear in 23% to 44% of pa-
tients after schizonticidal treatment [11,12]. They are due
to the persistence of hepatocytic dormant stages of the
parasite, known as hypnozoites. To date, the 8-aminoqui-
noline primaquine is the only antimalarial drug effective
against the hypnozoites that can be used to cure P. vivax
infection. Tafenoquine, a recently developed 8-aminoqui-
noline [11] is not yet available. However, there are three
main drawbacks in the use of 8-amino-quinolines: 1) they
may induce haemolytic anaemia in persons deficient in
glucose-6-phosphate dehydrogenase (a frequent condi-
tion in areas where P. vivax is endemic); 2) they are not
registered in several countries; and 3) primaquine-resist-
ant P. vivax is now emerging [13]. Therefore, new anti-re-
lapse drugs need to be developed. We speculated that
azithromycin, an azalid antibiotic analogue to erythromy-
cin, might be an anti-relapse drug of interest. Indeed, azi-
thromycin achieves high tissue concentrations; it is
mainly metabolised in the liver (where the hypnozoites
are sheltered) and it has an excellent therapeutic index
with the low level of toxicity characteristic of macrolide
antibiotics; it may also be used in children and pregnancy.
Azithromycin proved efficient in the prophylactic treat-
ment of P. vivax malaria [14], but it had a lower antima-
larial activity for the treatment of P. vivax attacks than
clindamycin or tetracyclines [15]. Azithromycin has no
hypnozoitocidal activity in rhesus monkeys infected with
P. cynomolgi B [16]. Yet, to our knowledge, the activity of
azithromycin on the hypnozoites of P. vivax has not been
tested. The purpose of this phase II clinical trial was to de-
termine whether azithromycin was effective enough in
preventing P. vivax relapses to warrant further evaluation
in phase III.
Figure 1
Design of the triangular test (upper boundary, Z = 2.58 – 1.51 V; lower boundary Z = -2.58 – 0.50 V) and the results of the
three sequential analyses. The Z and V statistics were calculated each time a patient relapsed. The corresponding points were
plotted on the graph and compared with the stopping boundaries. On the third analysis, the upper boundary was crossed,
causing the inclusion to be stopped.Malaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/13
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Methods
The hospital's Ethics Advisory Board (CCPRB Marseille 2)
approved the study protocol. All patients received written
and oral information, and appropriate informed consent
was obtained.
Patients
Criteria for inclusion in the study were: 1) P. vivax infec-
tion: body temperature ≥ 38°C and P. vivax identified in a
blood smear stained with Giemsa; 2) age from 18 to 70
years; 3) agreement to comply with the study protocol.
Criteria for non-inclusion in the study were: 1) other treat-
ment usually efficient against P. vivax administered at a
curative dose within 10 days before the inclusion; 2) fever
related to a condition other than P. vivax infection; 3) per-
sonal history of adverse reaction to macrolide or mac-
rolide-related drugs.
Study design
We carried out a non-comparative, open-label, phase II,
prospective study. The patients were administered azi-
thromycin 1.2 g once a day (two tablets of Azadose® 600
mg, Pfizer, 86 rue de Paris, F-91407 ORSAY Cedex) for 7
days (total dose 8.4 g). A member of the medical staff wit-
nessed each dosing. Body temperature was measured, any
adverse reaction was recorded, and blood smear examina-
tions were carried out every day during the first week, and
then once a week for five weeks. The parasite clearance
time is the time taken for parasite counts to fall below de-
tectable levels in a peripheral blood smear. The fever clear-
ance time is the time taken for the body temperature to
fall and remain below 38°C for >48 h. Transaminase lev-
els were measured at baseline, day 4, day 7, and day 28.
After the first six weeks of follow-up, the patients were in-
terviewed by telephone about relapses until they had
reached either an end point or the end of the study. When
a relapse infections occurred, the patient was treated with
chloroquine, 25 mg/kg total dose.
End point of interest
The end point of the study was the onset of a relapse in-
fection. A relapse was defined as a recurrence of a P. vivax
infection after day 28. Reinfection was excluded because
none of the patients left metropolitan France, where P.
vivax transmission do not occur, during the entire study
period.
Statistical analysis
This study was based on the TT [8,10]. We planned a con-
tinuous monitoring because P. vivax malaria has a rela-
tively low occurrence rate in our ward, and it was easy to
perform the analysis as the outcome for each new patient
became available. We designed the study to have a 5%
type I error and a 90% power (α = 0.05 and β = 0.10). We
considered that a relapse rate <12% indicated an adequate
clinical protection, and thus was the minimum detectable
improvement in relapse rate worthwhile to be detected at
the β = 10% level, while arelapse rate ≥ 45% indicated in-
sufficient protection [12,1]. Thus, H0 (p ≥ p0) and Ha (p
<pa) with p0 = 0.45 and pa = 0.12. The boundaries of the
triangular test, computed as described in the TT set-up sec-
tion above, were: Z = 2.58 – 1.51 V and Z = -2.58 – 0.50 V
(Figure 1).
Results
We included five patients, 3 males and 2 females aged 18–
32 years, in the study. Their baseline characteristics are
summarised in Table 1. Two patients acquired P. vivax in
the Comoro Islands, and three in India. The three patients
with a previous history of malaria may be considered as
immune. All the patients complied well with the treat-
ment, they all had an immediate adequate clinical re-
sponse; their body temperature returned below 38 C° in
less than 4 days. All patient were cured at day-28. We re-
corded only mild adverse events. Three patients com-
plained of nausea and abdominal discomfort occurring
within 30 to 60 minutes after each dosing; one patient (n°
3) reported loose stool emission two hours after each dos-
ing. The transaminase levels remained within the normal
range in all the patients. Three patients relapsed (relapse
rate 60%). At the time the third patient relapsed we
reached the conclusion that the relapse rate was not signif-
icantly different from the null hypotheses (Table 2 & Fig-
ure 1) and thus we stopped the trial.
Discussion
One advantage of conducting in a non-endemic country a
study aiming to evaluate the effectiveness of a drug effec-
tive on hypnozoites of P. vivax is that the relapse infec-
tions are easily distinguished from the reinfections, since
reinfection can occur only if the patient has travelled to an
endemic country during the follow-up period. One disad-
vantage, however, is the relatively low incidence of P vivax
infection; and thus the relatively small number of eligible
patients available. Another disadvantage is that a relapse
infection might occur more than two years after the infec-
tion. Because we wanted to avoid the complexity of a mul-
ti-centre design, the analysis would have been
considerably delayed to achieve an appropriate power lev-
el in a fixed-sample design. To meet all these require-
ments, we were compelled to choose a truly a sequential
decision-making method allowing to include the smallest
number of patients necessary to achieve an adequate pow-
er and to perform a continuous monitoring of a delayed
and infrequent outcome: the TT.
Using the TT, our findings clearly indicate that azithromy-
cin does not reliably prevent relapses in P. vivax infections.
This prompts us to conclude that the issue of the activity
of azithromycin against the hypnozoites of P. vivax doesMalaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/13
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not warrant further clinical studies. While we wanted to
adequately cure the P. vivax attacks, we did not want to use
another antimalarial drug which might have altered the
outcome of our patients. Pukrittayakamee et al. treated 18
patients infected with P. vivax with a 3-day course of azi-
thromycin (1.5 g total dose) [15]. Recrudescence was ob-
served in 89%. Although early relapses cannot be ruled
out, they are very unlikely because these patients were fol-
lowed up for only 28 days. Recrudescence might be due to
the insufficient free plasma and intra-erythrocytic [17]
concentrations of azithromycin resulting from an insuffi-
cient dosing and/or too short a duration of the treatment.
To allow for this, we administered a higher dose of azi-
thromycin for a longer (7-day) course. To our knowledge,
this is the first clinical trial in which as much as 8.4 g of
azithromycin has been administered. This regimen was
well tolerated (the recorded gastrointestinal adverse epi-
sodes were mild), and successfully cured all P. vivax at-
tacks. However, secondary outcomes derived from such a
small sample size study require very careful interpretation
and should not be generalised without caution.
Sequential tests are easy to use and their statistical proper-
ties are especially suitable to trials with straightforward
objectives such as phase II trials [18]. Unlike the conven-
tional fixed-sample design, the sequential design we used
in this study allowed for early termination when ineffica-
cy was clear. In sequential designs the sample size is a ran-
dom variable whose distribution depends on the true
treatment difference and on the stopping rule used. Usu-
ally, sequential designs will give sample size values which
are well below those needed in equivalent fixed-sample
designs [8]. Stimulation studies indicated that the use of a
TT-based sequential analysis design brought about a 50%
reduction of the average sample needed, when compared
to the fixed-sample design [10]. In the present study, if we
had used a fixed-sample design with identical criteria, the
sample size needed would have been 15 patients. Using
the a TT-based sequential analysis, sufficient information
Table 1: Characteristics, initial treatment outcome, and relapse pattern of patients infected with Plasmodium vivax and treated with 
azithromycin, 1.2 g once a day, for 7 days
Patients characteristics Initial treatment Relapse
N° Sex Age 
(years)
Previous 
malaria
Area of 
acquisition
Parasite clearancea 
(hours)
Fever clearanceb 
(hours)
Outcome End point 
(days)
5 F 26 No India 186 89 Relapsed 43
2 F 22 Yes India 65 51 Relapsed 45
4 M 32 No Comoros 161 42 Relapsed 108
1 M 32 Yes Comoros 96 24 Censored 396
3 F 18 Yes Comoros 161 17 Censored 407
a The parasite clearance time is the time taken for the parasite count to fall below detectable levels in a peripheral blood smear. b The fever clear-
ance time is the time taken for the body temperature to fall below 38°C and to remain below this value for >48 h.
Table 2: Sequential analysis of the Plasmodium vivax relapse rate in patients treated with azithromycin
Analysis No SNpZV Z  significant Z not significant
- 00000 - 2 . 5 8 2 . 5 8
1 1 2 0.50 0.10 0.50 -2.83 1.83
2 2 4 0.50 0.20 0.99 -3.07 1.08
3 35 0 . 6 0 0.75 1.24 -3.20 0.71
The trial was designed with the triangular test for p0 = 0.45, pa = 0.12, α = 0.05, and β = 0.10. S denotes the number of relapses observed; N, the 
number of patients included; p, is the relapse rate; Z= S – N p0; and V = N p0 (1 - p0). The setting of the triangular test is detailed in the text. At the 
third analysis, the Z value exceeded the upper boundary value (bolded in the table). At this time, the data indicate that the study should stop, and 
we can conclude that azithromycin treatment has not significantly reduced the relapse rate of P. vivax infection.Malaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/13
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was accumulated to reach a conclusion as soon as the fifth
patient reached an end point. That is, we saved 67% of the
patient sample size. Moreover, inclusion in the study
could be stopped shortly after one year from the inclusion
of the first patient. This constituted a substantial gain in
time since the inclusions were initially planned over a
three year period. This makes the test not only economical
but also in line with ethical requirements and could make
a case for wider use of sequential designs in infectious dis-
ease clinical trials.
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